HY-PAM 25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hy-pam 25, and what generic alternatives are available?
Hy-pam 25 is a drug marketed by Teva and is included in one NDA.
The generic ingredient in HY-PAM 25 is hydroxyzine pamoate. There are nineteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the hydroxyzine pamoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hy-pam 25
A generic version of HY-PAM 25 was approved as hydroxyzine pamoate by SANDOZ on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HY-PAM 25?
- What are the global sales for HY-PAM 25?
- What is Average Wholesale Price for HY-PAM 25?
Summary for HY-PAM 25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| DailyMed Link: | HY-PAM 25 at DailyMed |
US Patents and Regulatory Information for HY-PAM 25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | HY-PAM 25 | hydroxyzine pamoate | CAPSULE;ORAL | 088713-001 | Mar 4, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
